The latest news for pharma industry insiders.

Cryoport's business unit, Cryogene, will be tasked with helping to foster the growth of Moffitt’s cell and gene therapy efforts.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, comments on how personalization could play a role in the future development of eSampling platforms.

The latest news for pharma industry insiders.

The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, shares his inspiration behind designing SampleHub.

The latest news for pharma industry insiders.

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, explains the value of an online portal that offers logistics flexibility.

The latest news for pharma industry insiders.

The collaboration is powered by the discovery and development of obesity, type 2 diabetes, and cardiovascular disease treatments.

The new form of the vaccine would remove the need for HCPs to combine the powder antigen and liquid adjuvant themselves prior to administering.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, describes the progression of the sample distribution process.

The program intends to address supply chain challenges surrounding product safety, traceability, and counterfeiting.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), describes the randomized clinical trial involving psilocybin that he participated in.

The latest news for pharma industry insiders.

What is the value in US adults addressing these risks, and how do social determinants of health play a role?

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), addresses the importance of stopping the spread of misinformation when it comes to psychedelics.

The deal is expected to be finalized by the first half of this year.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), explains why this resource is an asset, specifically for research in the psychedelic space.

The latest news for pharma industry insiders.

The move—one that meet’s industry standards—confirms the Cryoport company’s commitment to providing quality and safety in the cold chain solutions space.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), provides a peek into what the association has set out to accomplish.

The latest news for pharma industry insiders.